04:06 AM EDT, 09/24/2025 (MT Newswires) -- GE Healthcare Technologies ( GEHC ) has agreed to develop, manufacture and commercialize Lantheus' ( LNTH ) piflufolastat F18 for prostate cancer diagnostics and companion diagnostic use in Japan, the companies said Wednesday.

Under the exclusive licensing agreement, GE Healthcare ( GEHC ) will pay Lantheus ( LNTH ) an upfront license fee, development milestones and tiered royalties based on sales in Japan, the companies said.

The deal includes the transfer of regulatory dossiers, manufacturing competencies and technical support to allow GE Healthcare ( GEHC ) to pursue clinical development in Japan toward potential regulatory submissions and commercial launch, the companies said.

Piflufolastat F18 is used for positron emission tomography scans of lesions in men with prostate cancer, the companies said.